ViroPharma Inc. (VPHM)
-NasdaqGS | Prev Close: | 28.80 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 33.50 |
|---|
| Beta: | 1.52 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 19.58 - 31.36 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 648,977 |
|---|
| Market Cap: | 1.88B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest - sourcesat Reuters(Wed, Jun 19)
- The Zacks Analyst Blog Highlights: ViroPharma, National Oilwell Varco, Natural Gas Services Group, Dril-Quip and Lufkin IndustriesZacks(Wed, Jun 19)
- ViroPharma Up on Takeover RumorsZacks(Tue, Jun 18)
- ViroPharma soars on buyout rumorsat MarketWatch(Mon, Jun 17)
- Why ViroPharma Shares Spikedat Motley Fool(Mon, Jun 17)
- ViroPharma Stock Jumps On Buyout Rumorsat Investor's Business Daily(Mon, Jun 17)
- Niche drugmaker ViroPharma attracts takeover interest -sourcesat Reuters(Mon, Jun 17)
- ViroPharma Shares Rise on Report of Drug Company Deal Interestat Bloomberg(Mon, Jun 17)
- Midday Movers: ERJ, UTX, MDVN & Moreat CNBC(Mon, Jun 17)
- Orphan drugmaker ViroPharma attracts takeover interest: sourcesat Reuters(Mon, Jun 17)
- Orphan drugmaker ViroPharma attracts takeover interest -sourcesat Reuters(Mon, Jun 17)
- The Zacks Analyst Blog Highlights: ViroPharma, ExxonMobil, Summit Midstream Partners, Enerplus and Ferrellgas PartnersZacks(Thu, Jun 13)
- Orphan Drug Status for ViroPharma's MaribavirZacks(Wed, Jun 12)
- Can This Experimental Drug Be Brought Back From the Dead?at Motley Fool(Wed, Jun 12)
- Potential ViroPharma drug receives orphan statusAP(Tue, Jun 11)
Key Statistics
| Forward P/E (1 yr): | 38.40 |
|---|
| P/S (ttm): | 4.71 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.68 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.03 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -5.07 |
|---|
Business Summary
ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally.
View More